The Ovarian Cancer Institute, in partnership with Georgia Tech, has developed an a method to detect ovarian cancer that is highly accurate in patients with Stage 1 disease. The study, entitled “Highly-accurate metabolomic detection of early-stage ovarian cancer,” was published in the November 17th issue of Nature’s online journal “Scientific Reports.” “We are thrilled to provide women with such a highly accurate test,” says Dr. Benigno – CEO of the Ovarian Cancer Institute.
We are elated to offer new hope to women of the future and continue our projects for women of the present. While our diagnostic project is near completion, OCI/GT researchers continue their work on direct therapeutics to delete the disease more directly and in a less toxic manner.
At the Ovarian Cancer Institute we will continue our funding efforts for this successful research team. If you would like to support us please visit the Donate page.
For now, there is not a timeline of when the test will be available publicly. We are working diligently to bring it to market as quickly as possible!
See our recent media coverage here!